摘要
目的观察前列地尔联合黄芪注射液治疗早期糖尿病肾病的临床疗效。方法将90例早期糖尿病肾病患者随机分为治疗组和对照组各45例。2组患者均接受糖尿病饮食、控制血糖、血压及调脂治疗。对照组静脉滴注黄芪注射液(30ml,1次/d);治疗组另加前列地尔注射液(20μg,1次/d)。观察治疗前后2组患者的24h尿白蛋白排泄率(UAER)、尿β2微球蛋白(β2-MG)、血尿素氮(BUN)和血肌酐(Cr)水平的变化。全部病例进行临床观察4周。结果 2组患者治疗后UAER、β2-MG、BUN和Cr水平均较治疗前显著下降(P<0.05),治疗后治疗组患者上述指标改善程度显著高于对照组组,差异有统计学意义(P<0.05)。治疗过程中未出现严重不良反应。结论前列地尔联合黄芪注射液可显著改善早期糖尿病患者尿蛋白的排出,改善肾功能,是治疗早期糖尿病肾病的有效方法,值得临床推广应用。
Objective To observe the clinical effect of alprostadil injection combined with astragalus injection in the treatment of early diabetic nephropathy. Methods Ninety cases with early diabetic nephropathy were randomly divided into two groups with 45 case in each. On the base controlling of blood glucose、blood pressure and blood fat. The treatment group was treated with alprostadil injection（ 20μg,qd） and astragalus injection（ 30 ml,qd）,while the control group with astragalus injection（ 30 ml,qd） alone. All case were observed for 4 weeks. The changes of urinary albumin excretion rate（ UAER）,β2-MG,blood urea nitrogen（ BUN） and serum creatinine（ Cr） in the two groups were observed before the treatment and after the treatment. Results The levels of UAER,β2-MG,BUN and Cr in the two groups were all significantly decreased after treatment（ P〈0. 05）. The amplitude decrease of UAER,β2-MG,BUN and Cr was obviously higher in the treatment group than in the control group（ P〈0. 05）. No other adverse effect was observed. Conclusions Alprostadil injection combined with Astragalus injection treatment of early diabetic nephropathy is an effective way. Therefore,it deserves the application in clinic.
出处
《临床合理用药杂志》
2015年第20期5-6,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
糖尿病肾病
前列地尔注射液
黄芪注射液
Diabetic nephropathies
Alprostadil injection
Astragalus injection
